Brain Neurotherapy Bio, Inc.

This early-stage study tests whether a gene therapy called AAV2-GDNF is safe for people with Multiple System Atrophy (MSA), a rare and serious brain disorder. Nine adults aged 35-75 with MSA will receive either the gene therapy or a placebo. The main goal is to check for side eff…